How a Cell Signaling Pathway Helps Macrophages Kill Cancer Cells
Author Information
Author(s): Joshi Trupti, Ganesan Latha P., Cheney Carolyn, Ostrowski Michael C., Muthusamy Natarajan, Byrd John C., Tridandapani Susheela
Primary Institution: The Ohio State University
Hypothesis
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated antibody-dependent cellular cytotoxicity (ADCC) against B cell lymphoma.
Conclusion
The PtdIns 3-kinase/Akt pathway is critical for macrophage-mediated cytotoxicity against Rituximab-coated B cell lymphomas by promoting effective contact between macrophages and tumor cells.
Supporting Evidence
- Macrophages primed with IFNγ showed increased cytotoxicity against Rituximab-coated B cell lymphoma.
- Inhibition of the PtdIns 3-kinase pathway completely abolished macrophage cytotoxicity.
- Myr-Akt expressing macrophages displayed significantly enhanced ability to mediate ADCC.
Takeaway
This study shows that a specific signaling pathway helps immune cells called macrophages to better kill cancer cells that are coated with antibodies.
Methodology
The study used human B cell lymphoma coated with Rituximab as the tumor target and murine macrophages primed with IFNγ as the effectors to analyze the role of the PtdIns 3-kinase/Akt pathway in ADCC.
Limitations
The study primarily focused on a specific type of lymphoma and may not be generalizable to all cancer types.
Participant Demographics
Murine macrophages and human B cell lymphoma cells were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website